PathogenDx Secures Tens of Millions in Funding to Advance mNGS-Based Pathogen Detection

VCBeat (WeChat: vcbeat) has learned that Tanyin Medical Technology Co., Ltd. (hereinafter referred to as “Tanyin Medical”) recently completed a financing round worth tens of millions of yuan, led by Wuchan Zhongda Hongcheng Investment. The funds will be primarily allocated to strategic initiatives including product research and development upgrades, deepening clinical services and scientific research collaborations, and strengthening medical brand promotion. Previously, in October 2020, Tanyin Medical secured tens of millions of yuan in angel-round funding from Lanwan Capital.

Tanyin Medicine adheres to the belief of “exploring the depths to uncover the hidden, identifying origins to clarify causes,” and has always focused on the research and development of clinical molecular diagnostic products for pathogenic microorganisms, as well as providing clinical testing services based on metagenomic next-generation sequencing (mNGS). Its core team was among the first in China to enter the clinical application field of pathogen metagenomic next-generation sequencing. The company has established medical laboratories in Shanghai, Guangzhou, Beijing, Chengdu, and other cities, with its business coverage extending across 25 regions nationwide. To date, it has cumulatively processed over 80,000 test samples and published dozens of high-quality SCI papers, includingThe first high-impact Chinese methodological paper on mNGS (Small Methods; Impact Factor: 14.18) was selected as one of the Top 10 Industry Publications of 2021The company currently collaborates with over 300 Grade A tertiary hospitals across China, providing in-depth services to clinical departments including critical care, respiratory medicine, hematology, and infectious diseases, while offering a one-stop mNGS pathogen detection solution for clinical laboratories.

Dr. Fang Yuan, Founder of Tanyin MedicineIt stated: The company pioneered the launch of its mNGS bloodstream detection product, Yixueyuan, in March 2021.^®, significantly improving the positive detection rate of pathogens in bloodstream infections while ensuring the detection rate of pathogen cfDNA; in October of the same year, Tanyin Medicine launchedThe industry’s first Pathoselect™ pathogen data analysis pipeline with 27,000+ entries, while enhancing analytical performance, it better leverages the research-oriented attributes of mNGS technology, providing more precise and comprehensive pathogen genomic data for clinical research. Tanyin Medicine actively participates in the establishment of industry standards, serving as a key contributor to the expert consensus on the first clinical specimen submission guidelines for respiratory infections and the detailed rules for interpreting mNGS reports within the industry. With the development of the industry, the company will continue to promote independent research and technological innovation, further solidifying high-throughput pathogen genetic testing technology, and consistently focusing on clinical needs to contribute to the significant growth of the infectious disease testing sector.

Wuchan Zhongda Hongcheng Investment: Hongcheng Investment is a subsidiary of Wuchan Zhongda Group Co., Ltd. (600704). As a large provincial state-controlled enterprise group in Zhejiang Province, Wuchan Zhongda Group has been consecutively listed among the Fortune Global 500 since 2011, has topped the list of Zhejiang’s Top 100 Enterprises for many years, and holds a dual AAA corporate credit rating. Serving as the investment platform of Wuchan Zhongda Group, Hongcheng Investment boasts extensive experience in investing in biopharmaceuticals, medical devices, and clinical services. By adopting a dual-drive strategy leveraging both industry operations and capital, Hongcheng Investment further strengthens industrial incubation to expand and enhance Wuchan Zhongda’s pharmaceutical investment sector.

Mr. Shen Yao, Chairman and General Manager of Wuchan Zhongda Hongcheng InvestmentUMC CAPITAL stated: "We have always been bullish on the foundational role of high-throughput gene sequencing technology in the precision medicine industry. The application of mNGS technology focuses on critical clinical needs, particularly enabling timely etiologic diagnosis and guiding clinical medication for patients with acute and critical illnesses. Previously, the slow development of pathogen identification technologies constrained the field; however, the emergence and advancement of mNGS pathogen detection technology will significantly drive substantial growth in the clinical infectious disease testing market. We highly recognize the strong competitive advantages that TanYin Medicine’s core team has accumulated over the years in R&D, clinical academic promotion, product registration, and efficient execution. We are confident that TanYin Medicine will continue to deepen its expertise in the field of precision diagnostics for infections, consistently launching testing services and products that meet clinical demands."